Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy GlaxoSmithKline (GSK) shares

Learn how to easily invest in GlaxoSmithKline shares.

GlaxoSmithKline plc (GSK) is a leading drug manufacturers-general business based in the US. It opened the day at USD$45.31 after a previous close of USD$45.06. During the day the price has varied from a low of USD$45.22 to a high of USD$45.6689. The latest price was USD$45.47 (25 minute delay). GlaxoSmithKline is listed on the NYSE and employs 90,096 staff. All prices are listed in US Dollars.

How to buy shares in GlaxoSmithKline

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – GSK – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Compare share trading platforms

Name Product Available Investment Types Min. Monthly Fee Available Markets
Sharesies
Shares, ETFs, Managed Funds, Index Funds
$0
US, NZ, AU, Funds with exposure to multiple markets
Trade and invest in more than 8,000 companies, ETFs and managed funds across New Zealand, the US and Australia.
OFFER
BlackBull Markets Share Trading
Shares
$0
US, NZ, AU, Funds with exposure to multiple markets
Exclusive: Sign up through Finder and get 5 free shares with a minimum first time deposit of $1,000. T&Cs apply.
Trade 23,000+ shares and access 80+ global markets across the US, New Zealand, Australia and more, plus benefit from extended trading hours, no monthly fees, 24/6 dedicated local support and a mobile trading app available on both Android and iOS.
Rockfort Markets Share Trading
Rockfort Markets Share Trading
Shares
$20
US, AU, Funds with exposure to multiple markets
Trade shares in more than 1000 companies across the US, Australia and more.
Low brokerage on trades, plus access to professional tools, research and live market data. Available on desktop and mobile.
OFFER
Tiger Brokers
Shares, ETFs, Options
$0
US, AU, Funds with exposure to multiple markets
Sign up to Tiger Brokers and get a free stock voucher worth NZ$10, plus receive 3 Rocket Lab shares and one lucky draw ticket to win a free share when you deposit at least NZ$500 into your Tiger account. Offer is for new clients only and is subject to minimum deposit requirements. T&Cs apply.
Trade shares in more than 7,000 companies across the US, Australia and Asia.
OFFER
Hatch
Shares, ETFs
$0
US
Sign up to Hatch through Finder and get a $20 top-up when you deposit $100 or more.
Invest in more than 4,100 US companies and exchange-traded funds (ETFs) - no minimum investment or monthly fees.
OFFER
Stake
Shares
$0
US
Sign up through Finder and use referral code "FINDERNZ" for a free stock valued up to US$150.
Trade more than 4,500 US-listed stocks and ETFs through Stake with $0 fees on trades.
loading

Compare up to 4 providers

GlaxoSmithKline shares at a glance

Information last updated 2022-01-14.
Open$45.31
High$45.67
Low$45.22
Close$45.47
Previous close$45.06
Change $0.41
Change % 0.9099%
Volume 3,395,971
Information last updated 2022-05-23.
52-week range$36.43 - $46.59
50-day moving average $44.23
200-day moving average $42.50
Wall St. target price$49.81
PE ratio 17.8452
Dividend yield $0.75 (4.46%)
Earnings per share (TTM) $2.52

GlaxoSmithKline stock price (NYSE:GSK)

Use our graph to track the performance of GSK stocks over time.

GlaxoSmithKline price performance over time

Historical closes compared with the close of $45.47 from 2022-05-24

1 week (2022-05-18) 4.22%
1 month (2022-04-26) 2.43%
3 months (2022-02-25) 6.54%
6 months (2021-11-26) 10.85%
1 year (2021-05-26) 17.46%
2 years (2020-05-26) 11.58%
3 years (2019-05-24) 13.17%
5 years (2017-05-25) 6.81%

Is GlaxoSmithKline under- or over-valued?

Valuing GlaxoSmithKline stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of GlaxoSmithKline's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

GlaxoSmithKline's P/E ratio

GlaxoSmithKline's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, GlaxoSmithKline shares trade at around 18x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

GlaxoSmithKline's PEG ratio

GlaxoSmithKline's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.9095. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into GlaxoSmithKline's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

GlaxoSmithKline's EBITDA

GlaxoSmithKline's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $10.8 billion.

The EBITDA is a measure of a GlaxoSmithKline's overall financial performance and is widely used to measure a its profitability.

GlaxoSmithKline financials

Revenue TTM $36.5 billion
Operating margin TTM 23.4%
Gross profit TTM $22.7 billion
Return on assets TTM 6.36%
Return on equity TTM 27.51%
Profit margin 14.02%
Book value $6.43
Market capitalisation $114.3 billion

TTM: trailing 12 months

GlaxoSmithKline share dividends

60%

Dividend payout ratio: 59.9% of net profits

Recently GlaxoSmithKline has paid out, on average, around 59.9% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.46% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), GlaxoSmithKline shareholders could enjoy a 4.46% return on their shares, in the form of dividend payments. In GlaxoSmithKline's case, that would currently equate to about $0.75 per share.

GlaxoSmithKline's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

GlaxoSmithKline's most recent dividend payout was on 30 June 2022. The latest dividend was paid out to all shareholders who bought their shares by 18 May 2022 (the "ex-dividend date").

Have GlaxoSmithKline's shares ever split?

GlaxoSmithKline's shares were split on a 2:1 basis on 11 November 1991. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your GlaxoSmithKline shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for GlaxoSmithKline shares which in turn could have impacted GlaxoSmithKline's share price.

GlaxoSmithKline share price volatility

Over the last 12 months, GlaxoSmithKline's shares have ranged in value from as little as $36.4262 up to $46.5936. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while GlaxoSmithKline's is 0.2895. This would suggest that GlaxoSmithKline's shares are less volatile than average (for this exchange).

GlaxoSmithKline overview

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc. ; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involve substantial risk of loss and therefore are not appropriate for all investors. Past performance is not an indication of future results. Consider your own circumstances and obtain your own advice before making any trades.

More guides on Finder

Go to site